Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSH BiopharmROCO:8432 84 Interest Coverage is 212.06 as of Dec. 2025, which is 69% below its 10-year median of 689.67. GuruFocus rates ROCO:8432 with a GF Score™ of 84/100 and a GF Value™ of NT$78.92 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 687 Drug Manufacturers companies, TSH Biopharm ranks better than 87.63% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. TSH Biopharm's
Operating Income
for the
three
months ended in Dec. 2025 was NT$42 Mil. TSH Biopharm's Interest Expense for the
three
months ended in Dec. 2025 was NT$-0 Mil.
TSH Biopharm's interest coverage for the quarter that ended in Dec. 2025 was 212.06.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. TSH Biopharm Corp Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for TSH Biopharm's Interest Coverage or its related term are showing as below:
ROCO:8432'
s Interest Coverage Range Over the Past 10 Years
Min: 89.67 Med: 689.67 Max: No Debt
Current: 275.11
ROCO:8432's Interest Coverage is ranked better than 87.63% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs ROCO:8432: 275.11
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
TSH Biopharm Interest Coverage Related Terms
TSH Biopharm Interest Coverage Historical Data
* Premium members only.
The historical data trend for TSH Biopharm's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ROCO:8432 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TSH Biopharm Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's Interest Coverage distribution charts can be found below:
* The bar in red indicates where TSH Biopharm's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSH Biopharm (ROCO:8432) has a Interest Coverage of 212.06 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on TSH Biopharm and its competitors. This is 69% below median its historical median of 689.67. Over the past decade, TSH Biopharm's Interest Coverage has ranged from 89.67 to 10,000.00. According to the industry distribution chart, TSH Biopharm ranks #85 out of 687 companies in the Drug Manufacturers industry, placing it in the top 12.4%.
Is TSH Biopharm's Interest Coverage too high?
TSH Biopharm's current Interest Coverage of 212.06 is 69% below median its 10-year median of 689.67. Over the past 10 years, this metric has ranged from a low of 89.67 to a high of 10,000.00. The Drug Manufacturers industry median Interest Coverage is 12.75. TSH Biopharm's value of 212.06 is 1563.2% above this industry median. Based on the distribution chart, TSH Biopharm ranks #85 out of 687 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TSH Biopharm has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, TSH Biopharm ranks #85 out of 687 companies for Interest Coverage. This places TSH Biopharm in the top 12% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.75. TSH Biopharm's value of 212.06 is 1563.2% above this benchmark. Historically, TSH Biopharm's own Interest Coverage has ranged from 89.67 to 10,000.00 over the past decade. While the company's 10-year median is 689.67 vs. the industry median of 12.75, TSH Biopharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TSH Biopharm's current Interest Coverage of 212.06 is 1563.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on TSH Biopharm and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TSH Biopharm's current Interest Coverage is 212.06, which is 69% below median its own 10-year median of 689.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$78.92, compared to a current price of NT$50.20 — trading 36.4% below its estimated fair value. The current Interest Coverage is 212.06, which is 69% below median its 10-year median of 689.67 and 1563.2% above the Drug Manufacturers industry median of 12.75. TSH Biopharm's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current Interest Coverage is 212.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TSH Biopharm (ROCO:8432) Overvalued in 2026?
Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued.
The current stock price of NT$50.20 is trading 36.4% below its estimated GF Value™ of NT$78.92.
GuruFocus considers TSH Biopharm to be Significantly Undervalued.
Key valuation signals for ROCO:8432:
Interest Coverage: 212.06 (69% below median its 10-year median of 689.67)
GF Value™: NT$78.92 vs. price of NT$50.20 (36.4% below fair value)
Industry Position: 1563.2% above the Drug Manufacturers median (#85 of 687)
No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
84GF Score
Get the complete analysis for ROCO:8432
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8432 has been successfully added to your 
